Patents by Inventor LEILA NOETZLI

LEILA NOETZLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240150769
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Application
    Filed: October 16, 2023
    Publication date: May 9, 2024
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • Ketohexokinase (KHK) iRNA compositions and methods of use thereof
    Patent number: 11926832
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230416736
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the mucin 5B (MUC5B) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a MUC5B gene and to methods of treating or preventing a MUC5B-associated disease, such as a lung disease, e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), and/or pulmonary fibrosis, e.g., idiopathic pulmonary fibrosis (IPF), in a subject.
    Type: Application
    Filed: April 19, 2023
    Publication date: December 28, 2023
    Inventors: Leila Noetzli, Margaret Parker, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Jeffrey Zuber
  • KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230323363
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230126881
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a Fc fragment of IgG receptor and transporter (FCGRT) gene encoding neonatal Fc receptor (FcRn). The invention also relates to methods of using such RNAi agents to inhibit expression of the FCGRT gene or production of the FcRn protein and to methods of preventing and treating a hepatotoxicity-associated disorder, e.g., alcoholic hepatitis, iron overload, and hepatocellular carcinoma.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: AIMEE DEATON, MARGARET PARKER, LEILA NOETZLI, JAMES D. MCININCH
  • COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION
    Publication number: 20230040920
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the DNAJB 1-PRKAC A fusion gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of DNAJB 1-PRKAC A fusion.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 9, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: LEILA NOETZLI, HO-CHOU TU, PATRICK HASLETT, JAMES MCININCH